NEW YORK (GenomeWeb) – Researchers continue to develop applications for Bio-Rad's Droplet Digital PCR, and the firm last week highlighted three of the 18 presentations at the American Society of Human Genetics that described using the technology.
In an interview, representatives from the company also confirmed that Bio-Rad is in ongoing discussions with the US Food and Drug Administration to pursue 510(k) clearance for an oncology application using ddPCR.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
